Women with advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who were treated with immunotherapy ...

KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent ...

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

Merck & Co. Inc. MRK on Monday announced results from two late-stage clinical studies evaluating treatments for advanced or recurrent endometrial cancer at the European Society for Medical Oncology ...

Please provide your email address to receive an email when new articles are posted on . Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A new review finds that while cancer-associated fibroblasts clearly promote tumor growth and suppress natural killer cell ...

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s IMFINZI® ...